| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
CRISPR Therapeutics AG (NASDAQ: CRSP)
CRSP Technical Analysis
3
| As on 9th Jun 2023 CRSP STOCK Price closed @ 61.24 and we RECOMMEND Sell for LONG-TERM with Stoploss of 64.19 & Sell for SHORT-TERM with Stoploss of 65.78 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CRSPSTOCK Price
| Open | 67.91 | Change | Price | % |
| High | 68.26 | 1 Day | -1.35 | -2.16 |
| Low | 60.68 | 1 Week | -3.42 | -5.29 |
| Close | 61.24 | 1 Month | 11.81 | 23.89 |
| Volume | 2732848 | 1 Year | -21.49 | -25.98 |
| 52 Week High 83.78 | 52 Week Low 39.19 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CRSP Daily Charts |
CRSP Intraday Charts |
Whats New @ Bazaartrend |
CRSP Free Analysis |
|
|
CRSP Important Levels Intraday
| RESISTANCE | 75.85 |
| RESISTANCE | 71.16 |
| RESISTANCE | 68.27 |
| RESISTANCE | 65.37 |
| SUPPORT | 57.11 |
| SUPPORT | 54.21 |
| SUPPORT | 51.32 |
| SUPPORT | 46.63 |
CRSP Forecast April 2024
| 4th UP Forecast | 98.12 |
| 3rd UP Forecast | 86.29 |
| 2nd UP Forecast | 78.98 |
| 1st UP Forecast | 71.67 |
| 1st DOWN Forecast | 50.81 |
| 2nd DOWN Forecast | 43.5 |
| 3rd DOWN Forecast | 36.19 |
| 4th DOWN Forecast | 24.36 |
CRSP Weekly Forecast
| 4th UP Forecast | 76.52 |
| 3rd UP Forecast | 71.62 |
| 2nd UP Forecast | 68.59 |
| 1st UP Forecast | 65.56 |
| 1st DOWN Forecast | 56.92 |
| 2nd DOWN Forecast | 53.89 |
| 3rd DOWN Forecast | 50.86 |
| 4th DOWN Forecast | 45.96 |
CRSP Forecast2024
| 4th UP Forecast | 153.76 |
| 3rd UP Forecast | 124.09 |
| 2nd UP Forecast | 105.75 |
| 1st UP Forecast | 87.41 |
| 1st DOWN Forecast | 35.07 |
| 2nd DOWN Forecast | 16.73 |
| 3rd DOWN Forecast | -1.61 |
| 4th DOWN Forecast | -31.28 |
CRISPR Therapeutics AG ( NASDAQ USA Symbol : CRSP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CRSP Business Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. Address: Baarerstrasse 14, Zug, Switzerland, 6300
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service